

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC)
June 10, 2022
DRAFT AGENDA

TOPIC SUMMARY

June 10, 2022: Topic II:

The committee will meet in open session to discuss the biologic application (BLA) BLA 125717 from bluebird bio, Inc. for betibeglogene autotemcel (autologous CD34+ stem cells genetically modified with a lentiviral vector to contain a gene encoding functional beta-globin); the applicant has requested an indication for the “treatment of patients with β -thalassemia who require regular red blood cell transfusions.”

DAY 2: JUNE 10

EDT 10:00 a.m.	Opening Remarks: Call to Order and Welcome	Lisa Butterfield, Ph.D. (5 min) Chairperson Vice-President, PICI Research Center University of California, San Francisco
10:05 a.m.	Administrative Remarks, Roll Call, Introduction of Committee, Conflict of Interest Statement	Christina Vert, M.S. (15 min) Designated Federal Officer, CTGTAC DSAC, CBER, FDA
10:20 a.m.	FDA Opening Remarks	Wilson W. Bryan, M.D. (5 min) Director Office of Tissues and Advanced Therapies

Session 4: beta-thalassemia Efficacy and Safety

10:25 a.m.	Applicant Presentations	bluebird bio, Inc. (45 min)
	Introduction	Anne-Virginie Eggimann, MSc. Chief Regulatory Officer, bluebird bio, Inc.
	Unmet Medical Need	Sujit Sheth, MD Chief, Pediatric Hematology/Oncology & Professor of Clinical Pediatrics at Weill Cornell Medical Center
	Efficacy	Rich Colvin, MD, PhD Chief Medical Officer, bluebird bio, Inc.
	Safety	Ajay Singh, MD Vice President Pharmacovigilance, bluebird bio, Inc.

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC)
June 10, 2022
DRAFT AGENDA

	Benefit-Risk	Alexis Thompson, MD, MPH Chief, Hematology Children's Hospital of Philadelphia
11:10 a.m.	FDA Presentation Betibeglogene autotemcel (beti-cel) : BLA 125717 Clinical Considerations for Efficacy and Specific Safety in Transfusion Dependent β - thalassemia	Karl Kasamon, M.D. (45 min) OTAT Clinical Reviewer Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT) OTAT, CBER
11:55 a.m.	Clarifying Questions to Presenters	(30 min)
12:25 p.m.	LUNCH BREAK	(35 min)
1:00 p.m.	OPEN PUBLIC HEARING	(60 min)
Session 5: beta-thalassemia Discussion and Voting		
2:00 p.m.	Questions to the Committee/Committee Discussion/Voting/Member Remarks	(115 min)
3:55 p.m.	Closing Remarks	Peter Marks, M.D., Ph.D. (5 min) Director, CBER
4:00 p.m.	ADJOURNMENT	Christina Vert, M.S. Designated Federal Officer, CTGTAC DSAC, CBER, FDA